Skip to main content
. 2016 Mar 3;9(1):64–69. doi: 10.1016/j.tranon.2016.01.003

Figure 1.

Figure 1

Examples of PD-L1 immunohistocehmistry staining in NSCLC tumor specimens. PD-L1 staining is evident from the presence of the chromogranin (brown); the counterstain is hematoxylin (blue). PD-L1 strong positivity and weak positivity were defined as traceable to the clinical trial version of the assay, which is currently used in the pembrolizumab clinical trials.